Clarity Pharmaceuticals (ASX:CU6): Executive Chair Dr Alan Taylor on Phase 3, Co-PSMA & the Future of Prostate Cancer ImagingUntitled episode

Further Reading & Listening 🎧 GU Cast | Urology Podcast – "Is Copper the new Gold??! Co-PSMA trial in European Urology" https://www.podchaser.com/podcasts/gu-cast-urology-podcast-2221144/episodes/is-copper-the-new-gold-co-psma-292293994 📄 European Urology – Co-PSMA Trial Publication https://doi.org/10.1016/j.eururo.2026.03.001 These resources were referenced during the webinar and provide additional clinical context around the Co-PSMA trial and the development of Cu-64 SAR-bisPSMA. Can Clarity Pharmaceuticals (ASX:CU6) become a global leader in radiopharmaceuticals for prostate cancer? In this episode of the Homodeus Research Podcast, Dr Alan Taylor, Executive Chair of Clarity Pharmaceuticals, discusses the company's differentiated copper-based radiopharmaceutical platform, progress across its Phase 3 clinical programs, and the commercial opportunity for next-generation prostate cancer imaging and therapy. Dr Taylor explains why Clarity chose copper isotopes over conventional imaging agents, the science behind the company's proprietary SAR technology, and how its platform is designed to improve both cancer diagnosis and treatment. The discussion covers the landmark Co-PSMA study, progress across the CLARIFY, AMPLIFY and ACCURACY Phase 3 trials, manufacturing strategy, intellectual property, regulatory pathway, commercialisation plans and the long-term outlook for radiopharmaceuticals in oncology. The episode concludes with an extensive live investor Q&A covering competitive positioning, partnerships, M&A, manufacturing capacity, future pipeline expansion and the key catalysts investors should watch over the coming 12–24 months. Whether you're interested in biotechnology, nuclear medicine, oncology or ASX healthcare companies, this episode provides a comprehensive overview of one of Australia's leading radiopharmaceutical developers. Topics Covered - Introduction to Clarity Pharmaceuticals - Why copper isotopes may outperform existing imaging agents - The science behind the SAR technology platform - Co-PSMA clinical trial results - CLARIFY, AMPLIFY & ACCURACY Phase 3 programs - Commercialisation strategy - Manufacturing and intellectual property - Regulatory pathway and future milestones - Expansion beyond prostate cancer - Live investor Q&A